12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Omacor: Additional Phase III data

Additional data from a double-blind, Japanese Phase III trial in 611 patients showed that 2 and 4 g/day oral TAK-085 reduced triglycerides from baseline to week 12, the primary endpoint, by 10.9% and 22.7%, respectively, vs. 11.3% for 1.8 g/day eicosapentaenoic acid (EPA) (p<0.0001 for high-dose TAK-085 vs. placebo). On secondary endpoints, there were no significant differences...

Read the full 264 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >